Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Bocanegra

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
The Journal of Investigative Dermatology|September 4, 2022
The Regulators of Peroxisomal Acyl-Carnitine Shuttle CROT and CRAT Promote Metastasis in MelanomaIrene Lasheras-Otero, Iker Feliu, Alberto Maillo, et al.
Cancers|September 23, 2022
Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA VaccinationMiriam Echaide, Ibone Labiano, Marina Delgado, et al.
International Journal of Molecular Sciences|April 17, 2019
PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung CancerAna Bocanegra, Gonzalo Fernandez-Hinojal, Miren Zuazo-Ibarra, et al.
International Journal of Molecular Sciences|September 9, 2022
How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity CellsAnna Aiello, Mattia Emanuela Ligotti, Maider Garnica, et al.
International Journal of Molecular Sciences|September 9, 2022
How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity CellsMaider Garnica, Anna Aiello, Mattia Emanuela Ligotti, et al.
EMBO Molecular Medicine|July 19, 2024
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targetsLuisa Chocarro, Ester Blanco, Leticia Fernandez-Rubio, et al.
Oncology and Therapy|December 12, 2022
Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)Adrián Alegre, Gonzalo Benzo, Rafael Alonso, et al.
Journal of Personalized Medicine|July 2, 2021
A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating SubsetsEster Blanco, Maria Ibañez-Vea, Carlos Hernandez, et al.
EMBO Reports|June 27, 2023
Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancerAna Bocanegra, Gonzalo Fernández-Hinojal, Daniel Ajona, et al.
British Journal of Cancer|December 31, 2021
The multi-specific V<sub>H</sub>-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activityCarolyn J Edwards, Angelica Sette, Carl Cox, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
The Journal of Investigative Dermatology|September 4, 2022
The Regulators of Peroxisomal Acyl-Carnitine Shuttle CROT and CRAT Promote Metastasis in MelanomaIrene Lasheras-Otero, Iker Feliu, Alberto Maillo, et al.
Cancers|September 23, 2022
Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA VaccinationMiriam Echaide, Ibone Labiano, Marina Delgado, et al.
International Journal of Molecular Sciences|April 17, 2019
PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung CancerAna Bocanegra, Gonzalo Fernandez-Hinojal, Miren Zuazo-Ibarra, et al.
International Journal of Molecular Sciences|September 9, 2022
How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity CellsAnna Aiello, Mattia Emanuela Ligotti, Maider Garnica, et al.
International Journal of Molecular Sciences|September 9, 2022
How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity CellsMaider Garnica, Anna Aiello, Mattia Emanuela Ligotti, et al.
EMBO Molecular Medicine|July 19, 2024
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targetsLuisa Chocarro, Ester Blanco, Leticia Fernandez-Rubio, et al.
Oncology and Therapy|December 12, 2022
Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)Adrián Alegre, Gonzalo Benzo, Rafael Alonso, et al.
Journal of Personalized Medicine|July 2, 2021
A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating SubsetsEster Blanco, Maria Ibañez-Vea, Carlos Hernandez, et al.
EMBO Reports|June 27, 2023
Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancerAna Bocanegra, Gonzalo Fernández-Hinojal, Daniel Ajona, et al.
British Journal of Cancer|December 31, 2021
The multi-specific V<sub>H</sub>-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activityCarolyn J Edwards, Angelica Sette, Carl Cox, et al.
Pageof 4